Carlsbad, CA, 07/11/18– Argonaut Manufacturing Services, a contract development and manufacturing organization (CDMO) serving molecular diagnostic and biopharmaceutical companies, today announced it has reached a

First Contract Development & Manufacturing Organization to Install Carterra’s Next Generation Label-Free Biosensor to Support Antibody Discovery Services Business Salt Lake City, UT, USA and

Seattle, WA, April 16, 2018 – RareCyte, Inc., a global rare cell detection and liquid biopsy company announces its newest product, CyteFinder HT in conjunction

SAN DIEGO, Calif., and NANJING, JiangSu, March 26, 2018 – Agena Bioscience (Agena) and Simcere Diagnostics (Simceredx), the subsidiary of SIMCERE Pharmaceutical Group, announced today

Salt Lake City, Utah, USA… Carterra Inc., an innovative label-free biosensor company, announced today that it has sold multiple units of its new, fully integrated,

Additional Resources Will Drive Commercialization of Novel High-Throughput Label-Free Biosensor for Streamlined Antibody Characterization   Salt Lake City, Utah, USA…Carterra Inc., an innovative label-free biosensor

AUSTIN, Texas– Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests

October 24, 2017 Ann Arbor, MI: Aquaro Histology, Inc. (formerly known as Aquaro Biosystems, LLC) announced today the completion of a Series A funding round

San Diego, CA, September 27, 2017 – Agena Bioscience today announced a comparative study published in PLOS ONE highlighting the use of its mass spectrometry-based

TrakCel Solution will electronically link Iovance with clinical sites, contract manufacturing organizations and couriers to schedule and track TIL therapies for each patient SAN CARLOS,

TrakCel solution integration with Cell and Gene Therapy Catapult manufacturing centre enables needle-to-needle supply chain management at any scale London, UK, September 7, 2017 –

Seattle, WA, August 24, 2017 – RareCyte, Inc., a global rare cell detection and liquid biopsy company will use the funding to advance its commercial